Imidazopyridine 1 was identified from a phenotypic screen against P. falciparum (Pf) blood stages and subsequently optimized for activity on liver-stage schizonts of the rodent parasite P. yoelii (Py) as well as hypnozoites of the simian parasite P. cynomolgi (Pc). We applied these various assays to the cell-based lead optimization of the imidazopyrazines, exemplified by 3 (KAI407), and show that optimized compounds within the series with improved pharmacokinetic properties achieve causal prophylactic activity in vivo and may have the potential to target the dormant stages of P. vivax malaria.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137381 | PMC |
| http://dx.doi.org/10.1021/ml500244m | DOI Listing |
Publication Analysis
Top Keywords
lead optimization
8
optimization imidazopyrazines
8
imidazopyrazines class
4
class antimalarial
4
antimalarial activity
4
activity plasmodium
4
plasmodium liver
4
liver stages
4
stages imidazopyridine
4
imidazopyridine identified
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!